Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Summary

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

Timeline

Start

2024-08-26

Primary completion

2028-08

Completion

2029-06

Publications

• Biteghe FAN, Mungra N, Malindi Z, Chalomie NET, Stanislas KA, Yasmin-Karim S, Mike Makrigiorgos G, Chipidza FE, Akinrinmade OA, Sridhar S, Barth S, Ngwa W. The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer. Cancer Med. 2025 Sep;14(18):e71255. doi: 10.1002/cam4.71255.

Drugs

Indications